Fredun Pharmaceuticals raises paid-up capital to Rs 16.90 crore

Fredun Pharmaceuticals Limited reported paid-up equity share capital of Rs 16.90 crore at September 30, 2026, after allotting 1,10,25,380 bonus shares on July 16 and 1,60,533 shares through warrant conversion during the half year. The company retrospectively adjusted comparative earnings per share for the bonus issue.

How did Fredun Pharmaceuticals change its share capital?

Fredun Pharmaceuticals increased its reported paid-up equity share capital to Rs 16.90 crore at September 30, 2026 from Rs 16.54 crore at June 30, 2026. The increase during the September quarter was Rs 36.16 lakh, following the July bonus allotment and shares issued on conversion of warrants during the six months ended September 30, 2026.

The quarterly-results table reports paid-up equity share capital of Rs 16.90 crore at September 30, 2026, Rs 16.54 crore at June 30, 2026, Rs 14.17 crore at September 30, 2025 and Rs 16.42 crore at March 31, 2026. The September 2026 figure was Rs 2.73 crore above the figure reported for the corresponding quarter a year earlier.

The consolidated balance sheet separately reports equity share capital of Rs 16.90 crore at September 30, 2026, compared with Rs 5.47 crore at March 31, 2026. That presentation records the half-year balance-sheet movement, while the quarterly-results table presents share-capital figures across the reported quarterly and annual comparison periods.

What was Fredun Pharmaceuticals' bonus-share issue?

Fredun Pharmaceuticals allotted 1,10,25,380 fully paid-up bonus equity shares with a face value of Rs 10 each on July 16, 2026. The company issued two bonus equity shares for every one equity share held, meaning the allotment increased the number of shares held by eligible shareholders under a two-for-one ratio.

The filing links the bonus issue to the company’s per-share reporting rather than identifying it as a cash raise. The reported paid-up equity capital was Rs 16.90 crore at September 30, 2026, and the company said the bonus shares required retrospective adjustment of basic and diluted earnings per share, or EPS, for all comparative periods presented.

The filing does not state a market-price effect, a shareholder-value impact or an operating target arising from the 1,10,25,380-share allotment. It identifies the allotment date, the Rs 10 face value and the two-for-one ratio, while specifying the accounting treatment applied to comparative EPS under Indian Accounting Standard 33, or Ind AS 33.

How many warrants did Fredun Pharmaceuticals convert?

Fredun Pharmaceuticals allotted 1,60,533 equity shares on conversion of 1,60,533 warrants during the half year ended September 30, 2026. The company said it received the applicable consideration for the conversion and reflected the resulting increase in paid-up equity share capital in the results.

The warrant conversion was distinct from the 1,10,25,380-share bonus issue completed on July 16, 2026. The cash-flow statement records Rs 16.05 lakh under changes in issue of share capital, Rs 19.91 crore in issue of share premium and Rs 93.34 lakh in issue of share warrants for the half year, but it does not disclose the warrant exercise price or the warrant holders.

Total consolidated equity stood at Rs 330.43 crore at September 30, 2026, compared with Rs 278.11 crore at March 31, 2026. Within that total, other equity rose to Rs 313.53 crore from Rs 272.64 crore, while equity share capital was reported at Rs 16.90 crore at September 30, 2026 against Rs 5.47 crore at March 31, 2026 in the balance sheet.

Why did Fredun Pharmaceuticals adjust EPS comparatives?

Fredun Pharmaceuticals retrospectively adjusted basic and diluted EPS for every comparative period because of the two-for-one bonus issue. The company cited Ind AS 33, which governs EPS reporting, and said the adjustment applied to all comparative periods shown in the September 2026 results.

Fredun Pharmaceuticals calculated current-period basic and diluted EPS using the applicable weighted-average shares and dilutive potential equity shares. It also stated that quarterly and half-yearly EPS are not annualised, so the per-share results for the quarter and six months ended September 30, 2026 are not directly expressed as full-year measures.

The change in share base occurred alongside higher consolidated profit. Profit for the half year ended September 30, 2026 was Rs 31.71 crore, compared with Rs 16.20 crore in the corresponding half year of 2025, while September-quarter profit was Rs 18.57 crore against Rs 9.43 crore a year earlier.

What did Fredun Pharmaceuticals report for the first half?

Fredun Pharmaceuticals reported consolidated net sales or income from operations of Rs 493.61 crore for the half year ended September 30, 2026, up from Rs 262.99 crore a year earlier. Total income from operations increased to Rs 495.88 crore from Rs 265.15 crore, while total expenses rose to Rs 445.68 crore from Rs 243.40 crore.

The company reported a single operating segment, pharmaceutical and healthcare. Profit before tax increased to Rs 50.20 crore in the September 2026 half year from Rs 21.75 crore in the previous-year half, and tax expense rose to Rs 18.50 crore from Rs 5.55 crore.

Cash generated from operating activities was Rs 17.53 crore for the half year, compared with Rs 13.50 crore in the prior-year period. Investing cash outflow was Rs 24.18 crore, including purchase of fixed assets of Rs 41.86 crore, while net cash declined by Rs 9.61 crore to closing cash and bank balances of Rs 55.37 crore.

Conclusion

Fredun Pharmaceuticals combined a two-for-one bonus issue of 1,10,25,380 shares with conversion of 1,60,533 warrants in the first half of fiscal 2027. The actions were reflected in reported paid-up capital of Rs 16.90 crore at September 30, 2026, while comparative EPS was restated and half-year consolidated profit rose to Rs 31.71 crore from Rs 16.20 crore.

The filing does not disclose a warrant conversion price, the identity of warrant holders or a schedule for further conversions. Subsequent capital-structure disclosures can clarify whether additional warrant-related share issuance occurs and how the weighted-average share base used for EPS changes after the September 2026 reporting date.